Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Melanoma 56Carcinoma, Non-Small-Cell Lung 56Carcinoma, Renal Cell 34Neoplasms 33Neoplasm Metastasis 29Colorectal Neoplasms 23Squamous Cell Carcinoma of Head and Neck 22Pancreatic Neoplasms 22Carcinoma, Hepatocellular 21Carcinoma, Transitional Cell 18Lung Neoplasms 17Glioblastoma 15Ovarian Neoplasms 14Triple Negative Breast Neoplasms 13Breast Neoplasms 13Urinary Bladder Neoplasms 11Stomach Neoplasms 11Head and Neck Neoplasms 10Uveal Melanoma 9Recurrence 8Myelodysplastic Syndromes 8Lymphoma 8Leukemia, Myeloid, Acute 8Advanced Cancer 8Small Cell Lung Carcinoma 7Multiple Myeloma 7Kidney Neoplasms 7Hodgkin Disease 7Hematologic Neoplasms 7Glioma 7

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Xeroderma Pigmentosum × Nivolumab × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡